KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Times Interest Earned (2016 - 2023)

Historic Times Interest Earned for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Q2 2023 value amounting to -$19.33.

  • Supernus Pharmaceuticals' Times Interest Earned fell 40830.9% to -$19.33 in Q2 2023 from the same period last year, while for Mar 2024 it was -$14.94, marking a year-over-year decrease of 30091.21%. This contributed to the annual value of -$2.18 for FY2023, which is 13344.29% down from last year.
  • Supernus Pharmaceuticals' Times Interest Earned amounted to -$19.33 in Q2 2023, which was down 40830.9% from $3.44 recorded in Q1 2023.
  • In the past 5 years, Supernus Pharmaceuticals' Times Interest Earned ranged from a high of $21.54 in Q4 2022 and a low of -$19.33 during Q2 2023
  • In the last 5 years, Supernus Pharmaceuticals' Times Interest Earned had a median value of $5.87 in 2021 and averaged $4.58.
  • In the last 5 years, Supernus Pharmaceuticals' Times Interest Earned soared by 199602.38% in 2022 and then tumbled by 40830.9% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Times Interest Earned (Quarter) stood at $7.07 in 2019, then fell by 0.17% to $7.05 in 2020, then tumbled by 85.43% to $1.03 in 2021, then skyrocketed by 1996.02% to $21.54 in 2022, then crashed by 189.73% to -$19.33 in 2023.
  • Its Times Interest Earned stands at -$19.33 for Q2 2023, versus $3.44 for Q1 2023 and $21.54 for Q4 2022.